Stock Research for ANTH

ANTH
Current Price

$1.2900


Latest Update: 2018-01-18 16:00:00

High
$ 1.2900
Low
$ 1.2800
Close
$ 1.2900
Volume
6025
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ANTH Stock Chart & Research Data

The ANTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ANTH Due diligence Resources & Stock Charts

The ANTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANTH Detailed Price Forecast - CNN Money CNN View ANTH Detailed Summary - Google Finance
Yahoo View ANTH Detailed Summary - Yahoo! Finance Zacks View ANTH Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ANTH Trends & Analysis - Trade-Ideas Barrons View ANTH Major Holders - Barrons
NASDAQ View ANTH Call Transcripts - NASDAQ Seeking View ANTH Breaking News & Analysis - Seeking Alpha
Spotlight View ANTH Annual Report - CompanySpotlight.com OTC Report View ANTH OTC Short Report - OTCShortReport.com
TradeKing View ANTH Fundamentals - TradeKing Charts View ANTH SEC Filings - Bar Chart
WSJ View Historical Prices for ANTH - The WSJ Morningstar View Performance/Total Return for ANTH - Morningstar
MarketWatch View the Analyst Estimates for ANTH - MarketWatch CNBC View the Earnings History for ANTH - CNBC
StockMarketWatch View the ANTH Earnings - StockMarketWatch MacroAxis View ANTH Buy or Sell Recommendations - MacroAxis
Bullish View the ANTH Bullish Patterns - American Bulls Short Pains View ANTH Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ANTH Stock Mentions - StockTwits PennyStocks View ANTH Stock Mentions - PennyStockTweets
Twitter View ANTH Stock Mentions - Twitter Invest Hub View ANTH Investment Forum News - Investor Hub
Yahoo View ANTH Stock Mentions - Yahoo! Message Board Seeking Alpha View ANTH Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ANTH - SECform4.com Insider Cow View Insider Transactions for ANTH - Insider Cow
CNBC View ANTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANTH - OTC Markets
Yahoo View Insider Transactions for ANTH - Yahoo! Finance NASDAQ View Institutional Holdings for ANTH - NASDAQ


Stock Charts

FinViz View ANTH Stock Insight & Charts - FinViz.com StockCharts View ANTH Investment Charts - StockCharts.com
BarChart View ANTH Stock Overview & Charts - BarChart Trading View View ANTH User Generated Charts - Trading View


Latest Financial News for ANTH

Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Wednesday January 17, 2018

NEW YORK, Jan. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera ...


Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
Posted on Tuesday January 09, 2018

HAYWARD, Calif., Jan. 09, 2018-- Anthera Pharmaceuticals, Inc. today announced that it has completed the second closing of the private placement of its equity securities with certain institutional and ...


Ultragenyx Announces Interim Data from Early Stage Study
Posted on Monday January 08, 2018

Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.


Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders
Posted on Monday January 08, 2018

HAYWARD, Calif., Jan. 08, 2018-- Anthera Pharmaceuticals, Inc. is pleased to announce the results of the Special Meeting of Stockholders held on January 5, 2018. Shareholders approved all of the proposed ...


Anthera Pharmaceuticals: Buy The Dip
Seeking Alpha - Nov 28, 2017
In this piece, I reiterate my bullish outlook on Anthera as a run-up play, suggesting that readers take advantage of the recent pullback.

Anthera Pharmaceuticals: Run Up Into Q1 Data
Seeking Alpha - Nov 15, 2017
The company ended the third quarter with $6.1 million of cash and does not include proceeds from the recent offering. Research and development expenses came in at $6.1 million, while general and administrative expense totaled $1.8 million.

Anthera Pharmaceuticals: A Series Of Unfortunate Events
Seeking Alpha - Aug 8, 2017
Anthera Pharmaceuticals is a clinical-stage biopharma company developing innovative therapies to improve existing treatments and enable treatment for unmet medical needs.

Anthera Pharmaceuticals Inc. (ANTH) Plunges 8.78% on January 15
Equities.com - Jan 15, 2018
Anthera Pharmaceuticals Inc. (ANTH) had a rough trading day for Monday January 15 as shares tumbled 8.78%, or a loss of $-0.13 per share, to close at $1.35.
What Is Insider Trading Activity Like At Anthera Pharmaceuticals, Inc. (ANTH)? - Economic News
23.7% Of Anthera Pharmaceuticals, Inc. (ANTH) Is Owned By Hedge Funds - Post Analyst

Enter a stock symbol to view the stock details.